The deal creates a new force in the world of value-based health care.
Kaiser Permanente and Geisinger Health said Wednesday they agreed to create a new company called Risant Health, which plans on making more acquisitions in the years to come.
Under the deal, Geisinger would become a part of Risant and keep its name. The agreement is subject to federal and state regulators.
Like California-based Kaiser and Pennsylvania-based Geisinger, Risant would be a nonprofit; it would be headquartered near Washington, DC.
“In addition to Geisinger, Risant Health will grow its impact by acquiring and connecting a portfolio of like-minded, nonprofit, value-oriented community-based health systems anchored in their respective communities,” according to a statement put out by the companies.
According to The Wall Street Journal, Risant seeks to acquire 4 or 5 more hospital systems and get to total revenue of $30 billion to $35 billion over the next 5 years, and Kaiser is expected to provide about $5 billion in funding to Risant.
Risant Health will operate separately from Kaiser Permanente, while health systems that join the new firm will also retain distinct identities in their communities.
Jaewon Ryu, MD, JD, who became Geisinger’s CEO in 2019, will become the new CEO of Risant Health.
Geisinger includes 10 hospital campuses, a health plan with more than half a million members, and has more than 25,000 employees and more than 1700 employed physicians.
"Through Risant Health, we will make our value-based care expertise, technology and services available to community-based health systems, like Geisinger, to strengthen their ability to provide value-based care models with a focus on high-quality and equitable health outcomes," said Greg. A. Adams, chair and CEO, Kaiser Permanente, in the statement.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen